DnA9V

159. Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relation
to breathlessness, and response to bronchodilator therapy. Respiratory Medicine.
1995;89(4):291-6.
160. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness
in palliative care A systematic review. Palliat Med. 2007;21(3):177-91.
161. Gallagher R, Roberts D. A systematic review of oxygen and airflow effect on relief of dyspnea
at rest in patients with advanced disease of any cause. Journal of Pain & Palliative Care Pharmacotherapy.
2004;18(4):3-15.
162. Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H. The use of oxygen in the
palliation of breathlessness. A report of the expert working group of the Scientific Committee
of the Association of Palliative Medicine. Respir Med 2004;98(1):66-77.
163. Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the
use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-44.
164. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double
blind, placebo controlled crossover trial of sustained release morphine for the management
of refractory dyspnoea. BMJ. 2003;327(7414):523-8.
165. Viola R, Kiteley C, Lloyd N, Mackay JA, Wilson R, and the Supportive Care Guidelines
Group. The Management of Dyspnea in Cancer Patients: A Clinical Practice Guideline. A
Quality Initiative of the Program in Evidence-based Care (PEBC). Disponible en: www cancercare
on ca/ [accedido en: septiembre 2007] 2007
166. Navigante AH, Cerchietti LCA, Castro MA, Lutteral MA, Cabalar ME. Midazolam as Adjunct
Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced
Cancer. Journal of Pain and Symptom Management. 2006;31(1):38-47.
167. Eng D. Management guidelines for motor neurone disease patients on non-invasive ventilation
at home. Palliat Med. 2006;20(2):69-79.
168. Watson MS, Lucas C.F, Hoy AM, Back IN. Respiratory symptoms. Oxford Handbook of
Palliative Care. New York: Oxford University press; 2005. p. 295-307.
169. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced cancer. Support Care
Cancer. 2001;9(8):565-74.
170. Estfan B, LeGrand S. Management of cough in advanced cancer. J Support Oncol. 2004;2(6):523-7.
171. Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell
lung cancer. Cochrane Database Syst Rev. 2006;(4):CD002143.
172. Kvale PA. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines.
Chest. 2006;129(1 Suppl):147S-53S.
173. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK, et al. The role of highdose-rate
brachytherapy in the palliation of symptoms in patients with non-small-cell lung
cancer: A systematic review. Brachytherapy. 2006;5(3):189-202.
174. Homsi J, Walsh D, Nelson KA, Sarhill N, Rybicki L, LeGrand SB, et al. A phase II study of
hydrocodone for cough in advanced cancer. American Journal of Hospice and Palliative
Medicine. 2002;19(1):49-56.
175. Luporini G, Barni S, Marchi E, Daffonchio L. Efficacy and safety of levodropropizine and
dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir
J. 1998;12(1):97-101.
296 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS